Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Autofagi-forsterkere for å redusere søvnforstyrrelser (SpSleep)

28. september 2026 oppdatert av: Nina Unger, University Medicine Greifswald

Autofagi-forsterkere for å redusere søvnforstyrrelser: En kombinert tilnærming

This clinical trial investigates the effects of spermidine supplementation on sleep quality and sleep-dependent memory consolidation in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), two populations at increased risk of future cognitive decline and dementia. Impaired sleep has been identified as a modifiable factor contributing to cognitive decline, and interventions targeting sleep architecture could offer therapeutic potential to prevent or slow down this decline.

Spermidine is a naturally occurring polyamine found in foods such as wheat germ and soybeans. It induces autophagy, a cellular degradation and recycling process essential for neuronal maintenance and function. In animal studies, spermidine has been shown to improve memory performance, reduce neuroinflammation, and support mitochondrial health. Preliminary findings from human trials in individuals with SCD or MCI suggest potential cognitive benefits of spermidine, but results are not unequivocal, and the impact on sleep has not been systematically evaluated.

In this randomized, double-blind, placebo-controlled trial, 76 participants aged 55 to 75 years with SCD or MCI will receive either spermidine (6 mg/day) or a placebo for 12 weeks. Sleep will be evaluated using overnight EEG in a controlled laboratory setting, focusing on measures such as slow-wave sleep and sleep spindle activity. Memory performance will be assessed before and after the intervention using standardized neuropsychological testing. Numerical skills will be tested at baseline only to compare SCD and MCI participants with healthy controls.

Blood samples will be collected to quantify metabolic indicators, neurodegeneration-related biomarkers, and autophagy-associated proteins. A control group of 38 cognitively healthy individuals will undergo comparable sleep and cognitive assessments without receiving any supplementation.

The primary objective of the study is to characterize the impact of spermidine on sleep-dependent memory consolidation and to identify associated biological changes relevant to aging and neurodegeneration. The results may inform the development of non-pharmacological strategies aimed at preserving cognitive function in individuals at risk for dementia.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) represent early stages along the continuum of cognitive decline preceding dementia. Individuals with SCD report persistent cognitive complaints despite normal performance on standardized cognitive testing, whereas MCI is characterized by objective cognitive impairment that does not yet interfere substantially with activities of daily living. Both conditions are associated with an elevated risk of progression to Alzheimer's disease and other dementias. Disruption of sleep architecture is increasingly implicated in the pathophysiology of neurodegenerative disorders, and early interventions targeting sleep-related mechanisms could help delay further cognitive decline. This clinical trial evaluates the effects of spermidine supplementation on sleep quality and sleep-dependent memory consolidation in older adults with SCD or MCI.

Following an adaptation night and an initial baseline sleep assessment with overnight electroencephalography (EEG), participants will be randomly assigned to either the spermidine or placebo group. The intervention consists of a daily oral dose of 6 mg spermidine (administered as three 2 mg sachets), continued over a 12-week period. The trial employs a randomized, double-blind, placebo-controlled design. Placebo sachets, identical in appearance and taste, contain only microcrystalline cellulose. After the 12-week supplementation period, participants will return for a second overnight EEG assessment.

A healthy control group (n=38), matched for age and sex, will undergo comparable baseline assessments but will not receive any intervention. These data will provide normative reference values for sleep and cognitive parameters.

The primary objective of the study is to assess the impact of spermidine on sleep architecture, measured via overnight polysomnography, with a specific focus on slow-wave sleep and sleep spindle activity, EEG markers associated with sleep-dependent memory consolidation and known to decline with age and neurodegeneration. Secondary outcomes include changes in memory consolidation (assessed using a battery of cognitive tasks that target declarative, procedural, and visuospatial memory domains), as well as numerical skills (tested via e.g., digit-letter-decision task, Berlin Numeracy Test). Testing occurs before and after each EEG night to evaluate overnight consolidation effects. All participants will wear actigraphs prior to both EEG nights to monitor sleep-wake cycles and physical activity.

Additional biological endpoints will examine changes in circulating neuropeptides, insulin-glucose homeostasis, and autophagy-related biomarkers. Blood samples are collected at each EEG session and two weeks after the start of supplementation. Physiological assessments include measurements of inflammatory markers (e.g., interleukin (IL)-6, tumor necrosis factor (TNF-α), neuroprotective factors (e.g., Neuropeptide Y, eukaryotic translation initiation factor 5A (eIF5A) hypusination), and metabolic indicators (e.g., fasting insulin, glucose, and lipid profiles).

Participants will undergo structural brain imaging using a 3-Tesla MRI scanner to exclude individuals with comorbid neurological conditions (e.g., prior stroke, other neurodegenerative diseases) and to assess brain morphology. Eligibility is determined through standardized pre-screening procedures, including clinical interviews and neuropsychological assessments.

The study includes 76 participants with SCD or MCI, aged 55-75 years, randomly allocated to either the spermidine or placebo group (n=38 per group). The sample size provides adequate statistical power to detect medium-to-large effect sizes, based on previous pilot findings and anticipated attrition rates.

This study aims to investigate the effects of spermidine supplementation on neurophysiological and cognitive outcomes in individuals with early-stage cognitive decline. The results are expected to contribute to the growing body of evidence evaluating spermidine as a safe, nutrition-based strategy for maintaining brain health and cognitive function in the context of aging.

Studietype

Intervensjonell

Registrering (Antatt)

76

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

  • Tyskland
    • Mecklenburg-Vorpommern
      • Greifswald, Mecklenburg-Vorpommern, Tyskland, 17475
        • Rekruttering
        • Department of Neurology, University Medicine Greifswald
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

55 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria (SCD participants):

  • Men and women

  • Written consent to participate in the study

  • German at native speaker level

  • Age between 55 and 75 years

  • Subjective Cognitive Decline operationalized as:

    1. Subjectively reported decline in cognitive function (particularly memory) despite objectively normal cognitive performance (e.g., WMS-LM)
    2. Preservation of functional independence
    3. No dementia

Inclusion Criteria (MCI patients):

  • Men and women

  • Written consent to participate in the study

  • German at native speaker level

  • Age between 55 and 75 years

  • Mild cognitive impairment (MCI) operationalized as:

    1. A change in cognitive abilities reported by the patient, relatives or clinic staff (i.e. historical or observed evidence of deterioration over time)
    2. Objective evidence of memory impairment (at least 1.0 Standard Deviation (SD) below the normal range on the Wechsler Logical Memory Scale (WMS-LM)); other cognitive domains may also be affected (i.e. amnestic MCI and amnestic + MCI)
    3. Preservation of independence of functional abilities
    4. No dementia

Exclusion Criteria (SCD and MCI participants):

  • Patients who are unable to give informed consent
  • Polyamine intake via dietary supplements and/or participation in corresponding intervention studies
  • Dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
  • Any condition that impairs clinical or neuropsychological examination procedures
  • Diabetes mellitus
  • Polycystic ovary syndrome
  • Signs of epilepsy, focal brain lesion or head injury with loss of consciousness or immediate post-injury confusion
  • Previous stroke
  • Severe untreated medical problems or unstable medical condition
  • Current major depressive episode
  • Psychotic disorder
  • Bipolar disorder
  • Current or previous substance abuse
  • Other neurodegenerative disease, e.g. Parkinson's disease
  • Vascular dementia
  • Alcohol abuse
  • Participation in an interventional study in the last 3 months and during the entire study period
  • Sleep disorders
  • Taking medication that primarily affects the central nervous system (e.g. antipsychotics, antidepressants, benzodiazepines or any type of over-the-counter sleep-inducing medication such as valerian; anti-dementia medication)
  • Known intolerances or allergies to wheat germ, gluten or histamine

Inclusion criteria (healthy controls):

  • Men and women
  • Written consent to participate in the study
  • German at native speaker level
  • Age between 55 and 75 years
  • Subjective cognitive disorders are denied

Exclusion criteria (healthy controls):

  • Subjects who are not able to give informed consent
  • Polyamine intake via dietary supplements and/or participation in corresponding intervention studies
  • Dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
  • Mild cognitive impairment (MCI), defined as described above in the patient inclusion criteria
  • Any condition that interferes with clinical or neuropsychological examination procedures
  • Diabetes mellitus
  • Polycystic ovary syndrome
  • Signs of epilepsy, focal brain lesion or head injury with loss of consciousness or immediate post-injury confusion
  • Previous stroke
  • Severe untreated medical problems or unstable medical condition
  • Current major depressive episode
  • Psychotic disorder
  • Bipolar disorder
  • Current or past substance abuse
  • Other neurodegenerative disease, e.g. Parkinson's disease
  • Vascular dementia
  • Alcohol abuse
  • Participation in an interventional study in the last 3 months and during the entire study period
  • Sleep disorders
  • Taking medication that primarily affects the central nervous system (e.g. antipsychotics, antidepressants, benzodiazepines or any type of over-the-counter sleep-inducing medication such as valerian; anti-dementia medication)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Kosttilskudd
Kosttilskudd: Spermidine Supplementation

supplementation of 6 mg Spermidine per day across 3 doses
Placebo komparator: Kostholdsmessig placebo
Kosttilskudd: Dietary Placebo

supplementation of 6 mg Placebo per day across 3 doses (placebo consists of maltodextrin, rice extract microcrystalline cellulose mixture, citric acid (anhydrous), silicon oxide (precipitated, E551))
Ingen inngripen: Healthy elderly controls

baseline comparison, healthy controls are not part of the intervention

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Effects of spermidine supplementation on sleep quality as measured by electroencephalography (EEG) mean power spectra
Tidsramme: baseline, 12-week follow-up

Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow oscillations (0.5-1 Hz), low delta (1-1.5 Hz), delta (1-4 Hz), theta (4-8 Hz), and beta (15-25 Hz).

For the spermidine effect, baseline and follow-up EEG data are compared with each other.
baseline, 12-week follow-up
Effects of spermidine supplementation on sleep quality as measured by sleep spindle count assessed from EEG
Tidsramme: baseline, 12-week follow-up

Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow frontal spindle (8-12 Hz), fast parietal spindle (12-15 Hz), and the number of slow frontal and fast parietal discrete spindles are counted. Spindle detection is performed based on an algorithm adopted from previous studies.

For the spermidine effect, baseline and follow-up EEG data are compared with each other.
baseline, 12-week follow-up
Effects of spermidine supplementation on sleep quality as measured by sleep spindle power assessed from EEG
Tidsramme: baseline, 12-week follow-up

Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow frontal spindle (8-12 Hz), fast parietal spindle (12-15 Hz). Spindle power is analyzed as a further measure of spindle activity. Spindle detection is performed based on an algorithm adopted from previous studies.

For the spermidine effect, baseline and follow-up EEG data are compared with each other.
baseline, 12-week follow-up
Effects of spermidine supplementation on sleep-related alertness as measured by computer-based task
Tidsramme: baseline, 12-week follow-up

The alertness task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. It comprises two runs without and two runs with a prior warning tone.

For the spermidine effect, baseline and follow-up task performances of SCD and MCI participants are compared with each other. Task performance is measured by speed (in ms) and hit/false or miss.
baseline, 12-week follow-up
Effects of spermidine supplementation on sleep-related visual-spatial memory as measured by computer-based task
Tidsramme: baseline, 12-week follow-up

The visual-spatial memory task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. After an encoding phase consisting of 60 objects (e.g., photo of a band-aid) placed in front of a background (e.g., photo of a treatment room in a doctor's office), a retrieval phase follows directly after encoding in the evening before bedtime, in which 30 randomly selected images from the total of 60 are tested. Participants should memorize the position of the object placed in front of the background and select the correct position by pressing a button.

In the next morning, the remaining 30 images are tested in a recall phase.

Task performance is measured by speed (in ms) and hit/false or miss.

For the spermidine effect, baseline and follow-up task performances of SCD and MCI participants are compared with each other.
baseline, 12-week follow-up
Effects of spermidine supplementation on sleep-related verbal memory as measured by computer-based task
Tidsramme: baseline, 12-week follow-up

The verbal memory task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. After an encoding phase consisting of 44 word pairs, a retrieval phase follows directly after encoding in the evening before bedtime, in which all word pairs are tested in randomized order. The next morning, all word pairs are tested in a recall phase.

Task performance is measured by hit/false or miss.

For the spermidine effect, baseline and follow-up task performances of SCD and MCI participants are compared with each other.
baseline, 12-week follow-up

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Differences in autophagy-related blood markers pre and post spermidine intervention in SCD and MCI as measured by polyamine concentration
Tidsramme: baseline, 2 weeks after baseline, 12-week follow-up

concentration in nmol / mg Protein assessed via Peripheral Blood Mononuclear Cells (PBMCs)
baseline, 2 weeks after baseline, 12-week follow-up
Differences in sleep quality between SCD or MCI and healthy controls (HC) as measured by electroencephalography (EEG) mean power spectra
Tidsramme: baseline data

Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow oscillations (0.5-1 Hz), low delta (1-1.5 Hz), delta (1-4 Hz), theta (4-8 Hz), and beta (15-25 Hz).

The differences between SCD / MCI and healthy controls are assessed from baseline EEG data.
baseline data
Differences in sleep quality between SCD or MCI and healthy controls (HC) as measured by sleep spindle count assessed from EEG
Tidsramme: baseline data

Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow frontal spindle (8-12 Hz), fast parietal spindle (12-15 Hz), and the number of slow frontal and fast parietal discrete spindles are counted. Spindle detection is performed based on an algorithm adopted from previous studies.

The differences between SCD / MCI and healthy controls are assessed from baseline EEG data.
baseline data
Differences in sleep quality between SCD or MCI and healthy controls (HC) as measured by sleep spindle power assessed from EEG
Tidsramme: baseline data

Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow frontal spindle (8-12 Hz), fast parietal spindle (12-15 Hz). Spindle power is analyzed as a further measure of spindle activity. Spindle detection is performed based on an algorithm adopted from previous studies.

The differences between SCD / MCI and healthy controls are assessed from baseline EEG data.
baseline data
Differences in autophagy-related blood markers pre and post spermidine intervention in SCD or MCI as measured by eIF5A hypusination
Tidsramme: baseline, 2 weeks after baseline, 12-week follow-up

assessed via Hypusinated eIF5A levels (Western Blot) from Peripheral Blood Mononuclear Cells (PBMCs)
baseline, 2 weeks after baseline, 12-week follow-up
Differences in neuropeptide Y blood levels pre and post spermidine intervention in SCD or MCI
Tidsramme: baseline, 12-week follow-up

Neuropeptide Y blood levels in pg/ml analyzed from serum blood sample
baseline, 12-week follow-up
Differences in sleep-related alertness between SCD or MCI participants and healthy controls as measured by computer-based task
Tidsramme: baseline

The alertness task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. It comprises two runs without and two runs with a prior warning tone.

The differences between SCD / MCI and healthy controls are assessed from baseline task data. Task performance is measured by speed (in ms) and hit/false or miss.
baseline
Differences in sleep-related visual-spatial memory between SCD or MCI participants and healthy controls as measured by computer-based task
Tidsramme: baseline

The visual-spatial memory task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. After an encoding phase consisting of 60 objects (e.g., photo of a band-aid) placed in front of a background (e.g., photo of a treatment room in a doctor's office), a retrieval phase follows directly after encoding in the evening before bedtime, in which 30 randomly selected images from the total of 60 are tested. Participants should memorize the position of the object placed in front of the background and select the correct position by pressing a button.

In the next morning, the remaining 30 images are tested in a recall phase.

Task performance is measured by speed (in ms) and hit/false or miss.

The differences between SCD / MCI and healthy controls are assessed from baseline task data.
baseline
Differences in sleep-related verbal memory between SCD or MCI participants and healthy controls as measured by computer-based task
Tidsramme: baseline

The verbal memory task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. After an encoding phase consisting of 44 word pairs, a retrieval phase follows directly after encoding in the evening before bedtime, in which all word pairs are tested in randomized order. The next morning, all word pairs are tested in a recall phase.

Task performance is measured by hit/false or miss.

The differences between SCD / MCI and healthy controls are assessed from baseline task data.
baseline
Differences in neuropeptide Y blood levels between SCD or MCI and healthy controls
Tidsramme: baseline data

blood levels in pg/ml analyzed from serum blood sample
baseline data
Differences in autophagy-related blood markers between SCD or MCI and healthy controls as measured by polyamine concentration
Tidsramme: baseline data

concentration in nmol / mg Protein assessed via Peripheral Blood Mononuclear Cells (PBMCs)
baseline data
Differences in autophagy-related blood markers between SCD or MCI and healthy controls as measured by eIF5A hypusination
Tidsramme: baseline data

assessed via Hypusinated eIF5A levels (Western Blot) from Peripheral Blood Mononuclear Cells (PBMCs)
baseline data
Differences in numerical skills between SCD or MCI patients and healthy controls as measured by lexical decision task
Tidsramme: assessed at baseline only

Participants complete a computer-based lexical decision task, in which a row of six symbols is presented after a fixation cross. Depending on the condition, the test subjects must decide by pressing a key on the keyboard whether the row presented contains a letter (e.g., condition 1) or a digit (e.g., condition 2). Each condition consists of two blocks. After the first block, there is a short pause before the second block starts. The condition (digit or letter) with which the trial starts is randomized for each test subject.
assessed at baseline only
Differences in numerical skills between SCD or MCI participants and healthy controls as measured by Berlin Numeracy Test
Tidsramme: assessed at baseline only

The Berlin Numeracy Test contains 4 short, text-based questions testing statistical numeracy and risk literacy, requiring Bayesian inference for problems like understanding probabilities in health concerns (e.g., poisonous mushrooms) or lotteries, often presenting data in relative/absolute numbers and asking for probability estimates. Correct answers scored for a total of 0-4 points.
assessed at baseline only

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

University Medicine Greifswald

Samarbeidspartnere

Department of Experimental Neuroimmunology, University Medicine
Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald
Institute of Biology, Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

28. oktober 2025

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. mai 2029

Datoer for studieregistrering

Først innsendt

17. september 2025

Først innsendt som oppfylte QC-kriteriene

28. januar 2026

Først lagt ut (Faktiske)

3. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • Autophagy and Sleep
  • 508402643 (Annet stipend/finansieringsnummer: Deutsche Forschungsgemeinschaft (DFG))

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere